HUTCHMED China Ltd (LON:HCM)
175p-2.78%
Spriggl Score: Moderate— see the number + sub-scores with a free Spriggl account
Last 30 trading days
Spriggl AI Verdict
“Outstanding kidney cancer data confirms drug platform works; more approvals coming; cash covers the wait.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About HUTCHMED China Ltd
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and p…
- Sector:
- Healthcare
- Industry:
- Drug Manufacturers - Specialty & Generic
- Market Cap:
- £1.5B
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
Sign up for a free Spriggl account to unlock the full Spriggl Score breakdown, screener, watchlist, and AI investment analysis on HUTCHMED China Ltd and 1,600+ UK and US stocks.
Start free